Related Experiment Video
Updated: Jun 21, 2026
06:21
Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
Published on: May 10, 2024
[MTHFR genetic variability on coronary artery disease development]
Patrícia Matos Biselli1, Alexandre Rodrigues Guerzoni, Eny Maria Goloni-Bertollo
1Faculdade de Medicina de São José do Rio Preto, São José do Rio Preto, SP.
Revista Da Associacao Medica Brasileira (1992)
|July 25, 2009
Summary
This study found no association between MTHFR gene polymorphisms (C677T and A1298C) and coronary artery disease (CAD) presence, extension, or severity. MTHFR variants do not appear to impact CAD risk or progression.
Area of Science:
- Genetics and Cardiovascular Medicine
- Biochemistry and Molecular Biology
- Population Genetics
Context:
- Elevated homocysteine (Hcy) is a known risk factor for coronary artery disease (CAD).
- MTHFR enzyme genetic variations can affect Hcy metabolism and potentially contribute to atherosclerosis.
- Investigating specific MTHFR polymorphisms (C677T and A1298C) is crucial for understanding CAD etiology.
Purpose:
- To investigate the relationship between MTHFR C677T and A1298C polymorphisms and the presence, extent, and severity of CAD.
- To determine if specific MTHFR genotypes are associated with increased risk or more advanced stages of coronary artery disease.
Summary:
- The study analyzed MTHFR C677T and A1298C polymorphisms in 175 CAD patients and 108 controls using PCR-based methods.
- Genotype distributions for both MTHFR polymorphisms did not significantly differ between CAD patients and controls.
- No significant association was found between MTHFR C677T or A1298C polymorphisms and the number of affected vessels or the degree of arterial obstruction.
Impact:
- This research indicates that common MTHFR polymorphisms (C677T and A1298C) are unlikely to be significant independent risk factors for CAD in the studied population.
- Findings contribute to clarifying the role of MTHFR gene variations in the pathogenesis of coronary artery disease.
- Results suggest that genetic screening for these specific MTHFR variants may not be clinically useful for CAD risk stratification.
More Related Videos
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:26Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...